Other Stories

AstraZeneca COVID-19 vaccines produced in S. Korea leave manufacturing plant Updated: 2021-02-25 14:37:58 KST

With one day to go until South Korea's COVID-19 vaccination program begins, the vaccines themselves are being transported from the manufacturing plant of SK Bioscience a South Korean drug maker that is producing AstraZeneca's vaccine under a partnership deal to the distribution center.
For more, we connect live to our Bae Eun-ji.
Eun-ji, give us more details about how the vaccines are being transported from there.

Connyoung, I'm standing outside the SK Bioscience vaccine manufacturing plant where, this morning, a truck departed carrying shots for 163-thousand people.
This area had been under strict military and police guard all morning before the truck carrying the vaccines left with a heavy police and military escort.
Since yesterday, two batches of doses have left here in the city of Andong in Gyeongsangbuk-do Province… 270 kilometers southeast of Seoul.
( 1)The vaccines are transported to a logistics warehouse in Icheon, Gyeonggi-do Province.
The shots will be temporarily stored there ( 2) before being delivered to almost 2-thousand public healthcare centers and nursing homes across the country.
By Sunday more than 1.5 million doses will have been moved to the logistics hub using a cold chain system.

That's good to hear. And SK Bioscience is also producing these vaccines to ship overseas?
That's right. Vietnam received its first batch of AstraZeneca vaccines produced here in Andong on Wednesday.
117-thousand doses that arrived in Ho Chi Minh City will be used to vaccinate more than 50-thousand people deemed to be high risk.
SK Bioscience will also be supplying 40 million doses of the Novavax vaccine for 20 million South Koreans starting this year.
The U.S. drug maker declared last week that SK Bioscience has obtained a license to manufacture and commercialize its vaccine to be sold to the Korean government.
That's all I have at this hour. Back to you, Connyoung.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.